Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Next Previous
X
Search
Trial Profile

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 28 Mar 2024 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2023 Results of five year interim analysis assessing effectiveness and safety data of blinatumomab in these pts presented at the 28th Congress of the European Haematology Association
    • 23 Mar 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top